Old Web
English
Sign In
Acemap
>
Paper
>
475 Targeting the JAK/STAT3 pathway with ruxolitinib for RDEB-cSCC therapy
475 Targeting the JAK/STAT3 pathway with ruxolitinib for RDEB-cSCC therapy
2019
J. Jackow
R. Hayashi
D. Owens
R. Perez-Lorenzo
C. Hansen
D. DeLorenzo
Z Guo
Angela M. Christiano
Keywords:
Ruxolitinib
STAT3
Cancer research
Immunology
Biology
Correction
Source
Cite
Save
Machine Reading By IdeaReader
0
References
0
Citations
NaN
KQI
[]